CHEWING GUM INCLUDING NANOZOME ENCAPSULATED CANNABIDIOL
20170265494 ยท 2017-09-21
Assignee
Inventors
Cpc classification
A61K47/18
HUMAN NECESSITIES
A61K9/2018
HUMAN NECESSITIES
A23G4/205
HUMAN NECESSITIES
A23G4/06
HUMAN NECESSITIES
A61K9/127
HUMAN NECESSITIES
A61K47/26
HUMAN NECESSITIES
A23G3/545
HUMAN NECESSITIES
A61K31/352
HUMAN NECESSITIES
A61K9/2072
HUMAN NECESSITIES
A61K47/24
HUMAN NECESSITIES
A23G4/20
HUMAN NECESSITIES
International classification
A23G4/20
HUMAN NECESSITIES
A61K47/18
HUMAN NECESSITIES
Abstract
Chewing gum including a liquid center, a chewy layer surrounding the liquid center, and a coating surrounding the chewy layer. The liquid center includes a nanozome encapsulated dose of a cannabinoid such as cannabidiol of approximately 1-30 mg. The nanozome is preferably a phospholipid such as a Phosphatidyl Choline. In another embodiment the nanozome is unsaturated Phosphatidyl Choline to improve bioavailability of the cannabidiol, or other cannabinoid.
Claims
1. Chewing gum comprising: a liquid center including a nanozome encapsulated cannabinoid; a chewy layer surrounding the liquid center; and a coating including a sweetener surrounding the chewy layer.
2. The chewing gum as set forth in claim 1, wherein the nanozome is a phospholipid.
3. The chewing gum as set forth in claim 2, wherein the phospholipid is Phosphatidyl Choline.
4. The chewing gum as set forth in claim 3, wherein the phospholipid is unsaturated.
5. The chewing gum as set forth in claim 4, wherein the phospholipid is derived from lecithin.
6. The chewing gum as set forth in claim 5, wherein the phospholipid is derived from soy lecithin.
7. The chewing gum as set forth in claim 4, wherein the phospholipid is derived from sunflower lecithin.
8. The chewing gum as set forth in claim 4, wherein the phospholipid is derived from egg yolk.
9. The chewing gum as set forth in claim 1, wherein the nanozome is a glycerophospholipids selected from the group consisting of: phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, and phosphatidic acid.
10. The chewing gum as set forth in claim 9, wherein the glycerophospholipid is extracted chemically using a non-polar solvent.
11. The chewing gum as set forth in claim 9, wherein the glycerophospholipid is extracted mechanically.
12. The chewing gum as set forth in claim 9, wherein the glycerophospholipid is extracted mechanically by water degumming the extracted oil of seeds, where the extracted oil is cold pressed.
13. The chewing gum as set forth in claim 9, wherein the glycerophospholipid is extracted mechanically and with heat.
14. The chewing gum as set forth in claim 9, wherein the glycerophosphoilipid is extracted from sunflower seed oil to be hypoallergenic.
15. The chewing gum as set forth in claim 9, wherein the glycerophosphoilipid is extracted from sunflower seed oil by mechanical means.
16. The chewing gum as set forth in claim 14, wherein the glycerophospholipid includes phosphatidylcholine in a concentration of at least 19%.
17. The chewing gum as set forth in claim 16, wherein the sweetener includes a steviol glycoside.
18. The chewing gum as set forth in claim 16, wherein the steviol glycoside is Rebaudioside A.
19. The chewing gum as set forth in claim 18, wherein the Rebaudioside A has been subject to enzymatic glycosylation to minimize flavor defects.
Description
BRIEF DESCRIPTION OF THE DRAWING
[0010]
DETAILED DESCRIPTION
[0011] Chewing gum according to the present invention includes a liquid center including a nanozome encapsulated cannabinoid, a chewy layer surrounding the liquid center and a coating including a sweetener surrounding the chewy layer. Cannabinoids include any phytocannabinoids derived from Cannabis Sativa, or a synthesized cannabinoid, or an endocannabinoid. The cannabinoids are preferably isolated in a purified form having a 90-99.9% purity. Terpenes derived from Cannabis Sativa having synergistic effects may be added in desired ratios. Cannabinoids are generally defined as any compound or molecule that directly effects the cannabinoid receptors CB1 or CB2 in humans.
[0012] Preferably, the cannabinoid utilized is a purified form of Cannabidiol (CBD), Tetrahydracannabinol (THC), Cannnabinol (CBN), Cannabigerol (CBG), or combinations thereof. An exemplary list of cannabinoids follows:
[0013] CBG (Cannabigerol)
[0014] CBC (Cannabichromene)
[0015] CBL (Cannabicyclol)
[0016] CBV (Cannabivarin)
[0017] THCV (Tetrahvdrocannabivarin)
[0018] CBDV (Cannabidivarin)
[0019] CBCV (Cannabichromevarin)
[0020] CBGV (Cannabigerovarin)
[0021] CBGM (Cannabigerol Monomethyl Ether)
[0022] THC (Tetrahydrocannabinol)
[0023] THCA (Tetrahydrocannbinolic acid)
[0024] CBD (Cannabidiol)
[0025] CBDA (Cannabidiolic Acid)
[0026] The chewy layer and coating are formulated in accordance with known ways of manufacture of chewing gum. In one embodiment the coating is a hardened and sweetened shell that resists heat and impact to maintain product integrity until consumed. The shell may be sweetened with a sucrose-based formulation, or a sugar-free formulation utilizing a polyol i.e. a sugar alcohol, or a polyol mixed with a high intensity sweetener such as a steviol glycoside.
[0027] In one embodiment of the invention, the nanozome is a phospholipid such as a Phosphatidyl Choline. In another embodiment the phospholipid is unsaturated, such as unsaturated Phosphatidyl Choline.
[0028] Preferably, the phospholipid is derived from a vegetable-sourced lecithin such as soy lecithin or sunflower lecithin. In another embodiment, the phospholipid is derived from non-plant sources such as egg yolk.
[0029] In other embodiments, the nanozome is a glycerophospholipids selected from the group consisting of: phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, and phosphatidic acid. These phospholipids can be used to encapsulated Cannabidiol to improve bioavailability, latency in vivo, and water solubility to optimize absorption through the mucusol membranes of the upper digestive tract, including the mouth, and to improve bioavailability on a cellular level.
[0030] The nanozome can be adapted in size and structure to optimize absorption into particular organs of the body, ie. musculature, nervous system, skeletal system, etc. Typically the nanozome has a size within the range of 50-800 nanometers.
[0031] There are various ways to extract glycerophospholipid from a source material. In one embodiment, the glycerophospholipid is extracted chemically using a non-polar solvent. In another embodiment, the glycerophospholipid is extracted mechanically, or mechanically with heat. In a variation of the invention, the glycerophospholipid is extracted mechanically by water degumming the extracted oil of seeds, where the extracted oil is cold pressed.
[0032] In a preferred embodiment of the invention, the glycerophosphoilipid is extracted from sunflower seed oil to be hypoallergenic. This extraction is performed by mechanical means.
[0033] In the liquid center of the chewing gum according to one aspect of the invention, the glycerophospholipid includes phosphatidylcholine in a concentration of at least 19%. The sweetener includes a steviol glycoside. Preferably, the steviol glycoside is Rebaudioside A that has been subject to enzymatic glycosylation to minimize flavor defects.
[0034]
[0035] A chewy layer 14 surrounds the liquid center. The chewy layer includes gum arabic and flavorings. A coating 16 surrounds the chewy layer. The coating is heat resistant to protect the piece of gum in ambient conditions including sunlight and ambient heat.